Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. WHO. Global Tuberculosis Report 2022 (2022). www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
- 2. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur. Respir. Rev. 31(164), 210264 (2022). •• Describes how two respiratory diseases can have a larger impact on human health and how one pandemic can be detrimental to fighting other pandemics.
- 3. Global Tuberculosis Report 2020 – reflections on the global TB burden, treatment and prevention efforts. Int. J. Infect. Dis. 113(Suppl. 1), S7–S12 (2021). • Considers the global tuberculosis (TB) burden, with the importance of future research.
- 4. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur. Respir. J. 55(3), 1901467 (2020). • This article is of interest as it reflects upon the shortening of TB regimens, while comparing it to individualized regimens which can be of greater importance in treating drug-resistant TB.
- 5. Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis. Lancet Respir. Med. 8(4), 334–335 (2020).
- 6. SeeTB: a novel alternative to sputum smear microscopy to diagnose tuberculosis in high burden countries. Sci. Rep. 9(1), 16371 (2019). • Discusses the novel and cost-effective diagnosis of TB,
- 7. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N. Engl. J. Med. 372(12), 1181–1182 (2015).
- 8. Estimation of subnational tuberculosis burden: generation and application of a new tool in Indonesia. Int. J. Tuberc. Lung Dis. 24(2), 250–257 (2020).
- 9. Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS Med. 16(2), e1002754 (2019).
- 10. . Getting to the point in point-of-care diagnostics for tuberculosis. J. Clin. Invest. 130(11), 5671–5673 (2020).
- 11. . Mycobacterium tuberculosis: a pathogen that can hold its breath a long time. Am. J. Respir. Crit. Care Med. 206(1), 10–12 (2022). • Focuses on an intricate conundrum in TB diagnosis and prevalence and the role of latent tuberculosis.
- 12. . Is Mycobacterium tuberculosis infection life long? BMJ 367, l5770 (2019).
- 13. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387(9), 810–823 (2022). •• Explains how combined antitubercular drugs show positive results against drug-resistant tuberculosis.
- 14. SARS-CoV-2 variants of concern are emerging in India. Nat. Med. 27(7), 1131–1133 (2021).
- 15. . Revisiting BCG to control tuberculosis: mucosal delivery and delipidation? Lancet Infect. Dis. 20(3), 272–273 (2020). •• Of considerable interest because bacille Calmette-Guérin has already been a cornerstone in immunization against TB. To understand how it can be modulated for better efficacy, especially in adults and via different routes, could play a major role in the end-TB strategy.
- 16. Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. Nat. Commun. 13, 602 (2022). •• Of considerable interest because the advent of an effective vaccine may be the ‘final nail in the coffin’ for TB.
- 17. . Eight countries eliminated a neglected tropical disease in 2022. Nature
doi.org/10.1038/d41586-023-00286-9 (2023) (Epub ahead of print).